Allergan PLC

Find Ratings Reports
AGN : NYSE : Health Care
$248.98 | %
Today's Range: 247.78 - 249.75
Avg. Daily Volume: 3,600,100
07/22/16 - 4:02 PM ET

Financial Analysis


ALLERGAN PLC's gross profit margin for the first quarter of its fiscal year 2016 has increased when compared to the same period a year ago. The company grew its sales and net income significantly quarter versus same quarter a year prior, and was able to outpace the average competitor in the industry when comparing revenue growth, but not when comparing net income growth. ALLERGAN PLC has very weak liquidity. Currently, the Quick Ratio is 0.48 which clearly shows a lack of ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year.

During the same period, stockholders' equity ("net worth") has increased by 8.46% from the same quarter last year. The key liquidity measurements indicate that the company is in a position in which financial difficulties could develop in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q1 FY16 Q1 FY15
Net Sales ($mil)3795.92562.6
EBITDA ($mil)1740.91002.4
EBIT ($mil)106.7157.4
Net Income ($mil)255.7-512.0


Balance Sheet Q1 FY16 Q1 FY15
Cash & Equiv. ($mil)2273.82130.9
Total Assets ($mil)136073.7139460.7
Total Debt ($mil)42567.544324.6
Equity ($mil)77450.071404.8


Profitability Q1 FY16 Q1 FY15
Gross Profit Margin83.7173.69
EBITDA Margin45.8639.11
Operating Margin2.816.14
Sales Turnover0.120.07
Return on Assets3.44-1.53
Return on Equity-3.15-4.5
Debt Q1 FY16 Q1 FY15
Current Ratio0.991.44
Debt/Capital0.350.38
Interest Expense332.8171.9
Interest Coverage0.320.92


Share Data Q1 FY16 Q1 FY15
Shares outstanding (mil)395.4392.3
Div / share0.00.0
EPS-0.38-2.8
Book value / share195.88182.02
Institutional Own % n/a n/a
Avg Daily Volume3745664.04515065.0

Valuation


HOLD. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. For additional comparison, its price-to-book ratio of 1.25 indicates a significant discount versus the S&P 500 average of 2.80 and a significant discount versus the industry average of 8.16. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, ALLERGAN PLC proves to trade at a discount to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
AGN NM Peers 45.53   AGN 18.46 Peers 29.24

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

AGN's P/E is negative making this valuation measure meaningless.

 

Discount. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

AGN is trading at a significant discount to its peers.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
AGN 14.00 Peers 16.57   AGN NA Peers 0.57

Average. An average price-to-projected earnings ratio can signify an industry neutral stock price and average future growth expectations.

AGN is trading at a valuation on par with its peers.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
AGN 1.25 Peers 8.16   AGN 49.96 Peers -19.18

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

AGN is trading at a significant discount to its peers.

 

Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

AGN is expected to have an earnings growth rate that significantly exceeds its peers.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
AGN 5.92 Peers 21.27   AGN 75.28 Peers 5.64

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

AGN is trading at a significant discount to its industry on this measurement.

 

Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.

AGN has a sales growth rate that significantly exceeds its peers.

 

 

Latest Stock Upgrades/Downgrades